Neurocrine Biosciences (NBIX) Net Income towards Common Stockholders (QoQ) (2010 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Net Income towards Common Stockholders (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.53 Bn | 625.77 Bn | 17.26 Bn |
| 2 | AbbVie | 442.27 Bn | 435.70 Bn | 12.70 Bn |
| 3 | Merck | 366.81 Bn | 359.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.82 Bn | 259.13 Bn | 11.24 Bn |
| 5 | Pfizer | 159.37 Bn | 147.67 Bn | 10.94 Bn |
| 6 | Sanofi | 52.46 Bn | 45.08 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.12 Bn | 44.12 Bn | - |
| 8 | Incyte | 25.49 Bn | 20.95 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.55 Bn | 18.89 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -27.03% |
| Mar 31, 2026 | 28.76% |
| Dec 31, 2025 | -26.63% |
| Sep 30, 2025 | 94.88% |
| Jun 30, 2025 | 1,260.76% |
| Mar 31, 2025 | -92.34% |
| Dec 31, 2024 | -20.57% |
| Sep 30, 2024 | 99.69% |
| Jun 30, 2024 | 49.77% |
| Mar 31, 2024 | -70.62% |
| Dec 31, 2023 | 77.74% |
| Sep 30, 2023 | -12.98% |
| Jun 30, 2023 | 224.67% |
| Mar 31, 2023 | -186.07% |
| Dec 31, 2022 | 29.93% |
| Sep 30, 2022 | 505.33% |
| Jun 30, 2022 | -221.58% |
| Mar 31, 2022 | 290.41% |
| Dec 31, 2021 | -132.44% |
| Sep 30, 2021 | -46.81% |